IPX066;治療藥物分析及市場預測 是由出版商GlobalData在2011年07月所出版的。
這份英文市場調查報告書包含Pages: 36 價格從美金2000起跳。
本報告提供帕金森氏症治療藥物的 IPX066 平台分析及市場預測，以市場特徵為首，評估分析競爭，開發平台等，加上未來市場競爭，企業簡介等資料，為您概述為以下內容。
1 目錄 1 目錄 2 簡介
- 2.1 帕金森氏症
- 2.2 症狀; 帕金森氏症
- 2.3 診斷; 帕金森氏症
- 2.4 帕金森氏症 治療策略
- 2.5 帕金森氏症 市場
- 2.6 免疫學
- 2.7 帕金森氏症, 年齡及性別
- 2.8 病因論
- 2.9 GlobalData 報告指南
3 帕金森氏症: 市場特性
- 3.1 帕金森氏症 市場
- 3.2 帕金森氏症 市場 預測及年複合成長率
- 3.3 影響因素; 帕金森氏症 市場
- 3.3.1 高患病率: 帕金森氏症是第二大常見的神經退化性疾病
- 3.3.2 老年人口的增加
- 3.3.3 專利期間的結束; 潛力治療藥物
4 分期; 帕金森氏症及治療方法比較
- 4.1 Hoehn-Yahr 分期法
- 4.2 修正 Hoehn-Yahr 分期法
- 4.3 UPDRS;帕金森氏症統一分期法
5 分期分類; 帕金森氏症
- 5.1 分佈; 帕金森氏症 患者, 各年齡層
- 5.2 各階段患者分佈
6 IPX066
- 6.1 簡介
- 6.2 作用機制
- 6.3 臨床研究
- 6.4 現狀; IPX066
- 6.5 銷售額的影響因素; IPX066
- 6.5.1 IPX066 ;帕金森氏症全分期的使用
- 6.5.2 高有效性
- 6.5.3 在日本未認證
- 6.6 醫藥品評估
- 6.6.1 藥物的風險·好處評估
- 6.6.2 競爭激烈度
- 6.7 銷售額預測
- 6.7.1 目標患者群; 帕金森氏症
- 6.7.2 投藥
- 6.7.3 市場滲透率
- 6.7.4 治療的年度成本;
- 銷售額預測; IPX066
7 帕金森氏症 市場: 附錄
- 7.1 市場定義
- 7.2 簡稱一覽
- 7.3 調查方法
- 7.3.1 調查範圍
- 7.3.2 二級研究
- 7.3.3 預測
- 7.3.4 可服用藥物的患者數
- 7.3.5 治療藥物的純市場滲透率
- 7.3.6 年度淨投藥數量
- 7.3.7 治療的年度成本;
- 7.3.8 主要研究
- 7.3.9 專家委員會
- 7.4 治療藥物的銷售額預期模式
- 7.5 諮詢方式
- 7.6 免責聲明
- 7.7 資訊來源
1.1 表格一覽
- 表格 1: 臨床運動及非運動症狀; 帕金森氏症
- 表格 2: 帕金森氏症的 Hoehn - Yahr 重症期
- 表格 3: 帕金森氏症的 Hoehn - Yahr 重症期
- 表格 4: UPDRS 之1，第4項
- 表格 5: 帕金森氏症 之2，第13項
- 表格 6: UPDRS 之3，第14項
- 表格 7: UPDRS 之3，第14項
- 表格 8: 分佈; 依Hoehn and yahr分期法分期的帕金森氏症患者
- 表格 9:比較; IPX066 Stalevo
- 表格 10:藥物的風險·好處評估 (DRB)- IPX066
- 表格 11: APEX 結果 -帕金森氏症 第三相 調查研究
- 表格 12: 主要試驗指標結果, 進行的帕金森氏症 第三相 調查研究
- 表格 13: 不利事件概要 , 進行的帕金森氏症 調查研究, 維護相
- 表格 14: 服用數量; APEX-PD 臨床實驗
- 表格 15: 年度成本; IPX066
- 表格 16: IPX066, 帕金森氏症, 全球市場, 銷售額預測 ($m)
- 表格 17: IPX066, 帕金森氏症, 美國, 銷售額預測 ($m)
- 表格 18: IPX066, 帕金森氏症, 英國, 銷售額預測 ($m)
- 表格 19: IPX066, 帕金森氏症, 法國, 銷售額預測 ($m)
- 表格 20: IPX066, 帕金森氏症, 德國, 銷售額預測 ($m)
- 表格 21: IPX066, 帕金森氏症, 義大利, 銷售額預測 ($m)
- 表格 22: IPX066, 帕金森氏症, 西班牙, 銷售額預測 ($m)
1.2 圖表一覽
- 圖 1: 最新的藥物療法; 帕金森氏症及潛在的作用部位 - CNS(中樞神經系統)
- 圖 2: 各年齡患病率; 帕金森氏症 - EU5個國家的老年人
- 圖 3: 帕金森氏症, 全球市場, 市場規模預測 ($bn)
- 圖 4: 60歲以上人口的比例, 全球, 1950-2050
- 圖 5: UPDRS的分數分佈
- 圖 6: 分佈; 依Hoehn and yahr分期法分期的帕金森氏症患者
- 圖 7: 一次試驗指標, Off 時間的減少, 進行的帕金森氏症 第三相 調查研究
- 圖 8: 二次試驗指標, UPDRS 之2及的3的改善, 進行的帕金森氏症 第三相 調查研究 結果
- 圖 9: Drug model diagram; IPX066
- 圖 10: IPX066, 帕金森氏症, 全球市場, 銷售額預測 ($m)
- 圖 11: IPX066, 帕金森氏症, 美國, 銷售額預測 ($m)
- 圖 12: IPX066, 帕金森氏症, 英國, 銷售額預測 ($m)
- 圖 13: IPX066, 帕金森氏症, 法國, 銷售額預測 ($m)
- 圖 14: IPX066, 帕金森氏症, 德國, 銷售額預測 ($m)
- 圖 15: IPX066, 帕金森氏症, 義大利, 銷售額預測 ($m)
- 圖 16: IPX066, 帕金森氏症, 西班牙, 銷售額預測 ($m)
- 圖 17: IPX066, 帕金森氏症, 全球市場, 各國銷售額分佈預測
- 圖 18: Drug model diagram
- 圖 19: 可服用藥物的患者數
Abstract
Summary
GlobalData's pharmaceuticals report, "IPX066 - Analysis and Estimates from 2013 to 2020" provides IPX066 sales estimates for US and EU5. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2013-2020). The report also includes information on Parkinson's Disease market. This report is built using data and information sourced from GlobalData's proprietary databases, primary and secondary research using Company's corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.
Scope
- Therapy area profile including patient population for the Japan (seven major markets)
- Analysis and review of IPX066 including sales data
- Qualitative and quantitative assessment of market space
- Analysis of the trends, drivers and restraints shaping and defining the markets
- In-depth analysis of IPX066 including efficacy, safety, pricing, competition and other details which influence its sales potential
- Detailed sales forecast for 2013-2020 for IPX066 in the US and EU5
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of competition by understanding the changing competitive landscape
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of the drug's performance
- Examine the historical sales performance of a drug in seven major markets
- Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets
Table of contents
1. Table of contents
- 1.1 List of Tables
- 1.2 List of Figures
2. Introduction
- 2.1 Parkinson's Disease
- 2.2 Symptoms of Parkinson's Disease
- 2.3 Diagnosis of Parkinson's disease
- 2.4 Parkinson's Disease Treatment Strategies
- 2.5 Parkinson's Disease Market
- 2.6 Epidemiology
- 2.7 Parkinson's Disease by Age and Gender
- 2.8 Etiology
- 2.9 GlobalData Report Guidance
3. Parkinson's Disease: Market Characterization
- 3.1 Parkinson's Disease Market
- 3.2 Parkinson's Disease Market Forecasts and CAGR
- 3.3 Factors Affecting Parkinson's Disease Market
- 3.3.1 High Prevalence: PD is the Second Most Frequent Neurodegenerative Disorder
- 3.3.2 Increase in Old Age Population
- 3.3.3 Patent Expiry of Prominent Drugs
4. Stages of Parkinson's Disease and Comparison of Treatments
- 4.1 The Hoehn and Yahr Scale
- 4.2 Modified Hoehn and Yahr Scale
- 4.3 The UPDRS
5. Staging of Parkinson's Disease
- 5.1 Distribution of Parkinson's disease Patients by Age Groups
- 5.2 Distribution of Patients by Stages
6. IPX066
- 6.1 Introduction
- 6.2 Mechanism of Action
- 6.3 Clinical Studies
- 6.4 Status of IPX066
- 6.5 Factors Affecting Sales of IPX066
- 6.5.1 IPX066 Used in All Stages of Parkinson's Disease
- 6.5.2 Better Efficacy
- 6.5.3 Not Approved in Japan
- 6.6 Drug Evaluation
- 6.6.1 Drug Risk Benefit Score
- 6.6.2 Intensity of Competition
- 6.7 Sales Forecasts
- 6.7.1 Target Patient Pool for Parkinson's Disease
- 6.7.2 Dosing
- 6.7.3 Market Penetration
- 6.7.4 Annual Cost of Therapy
- Sales Projections of IPX066
7. Parkinson Disease Market: Appendix
- 7.1 Market Definitions
- 7.2 List of Abberiviations
- 7.3 Research Methodology
- 7.3.1 Coverage
- 7.3.2 Secondary Research
- 7.3.3 Forecasting
- 7.3.4 Number of Patients Approved to take the Drug
- 7.3.5 Net Penetration of Drug
- 7.3.6 Net Annual Dosing
- 7.3.7 Annual Cost of Therapy
- 7.3.8 Primary Research
- 7.3.9 Expert Panels
- 7.4 Drug Sales Estimates Model
- 7.5 Contact Us
- 7.6 Disclaimer
- 7.7 Sources
List of Tables
- Table 1: Clinical Motor and Nonmotor Features of Parkinson's Disease
- Table 2: Hoehn and Yahr Stages of Parkinson's Disease
- Table 3: Hoehn and Yahr Stages of Parkinson's Disease
- Table 4: Four Items, Part 1 of UPDRS
- Table 5: Thirteen Items, Part 2 of Parkinson's disease
- Table 6: Fourteen Items, Part 3 of UPDRS
- Table 7: Fourteen Items, Part 3 of UPDRS
- Table 8: Distribution of Parkinson's patients according to Hoehn and Yahr Classification
- Table 9:Comparison of IPX066 with Stalevo
- Table 10:Drug Risk Benefit Score (DRB)- IPX066
- Table 11: Results of APEX -Parkinson's Disease Phase III Study
- Table 12: Primary Endpoints Results, Advanced- Parkinson's Disease Phase III Study
- Table 13: Summary of Adverse Events , Advanced PD Study, Maintenance Phase
- Table 14: Dosing Details of APEX-PD Clinical Trial
- Table 15: Annual Cost of IPX066 for Parkinson's Disease, 2010
- Table 16: IPX066, Parkinson's Disease, Global, Sales Forecasts ($m), 2013-2020
- Table 17: IPX066, Parkinson's Disease, The US, Sales Forecasts ($m), 2013-2020
- Table 18: IPX066, Parkinson's Disease, The UK, Sales Forecasts ($m), 2013-2020
- Table 19: IPX066, Parkinson's Disease, France, Sales Forecasts ($m), 2013-2020
- Table 20: IPX066, Parkinson's Disease, Germany, Sales Forecasts ($m), 2013-2020
- Table 21: IPX066, Parkinson's Disease, Italy, Sales Forecasts ($m), 2013-2020
- Table 22: IPX066, Parkinson's Disease, Spain, Sales Forecasts ($m), 2013-2020
List of Figures
- Figure 1: Current Pharmacologic Therapies for Parkinson's disease and Their Potential Sites of Action in the CNS
- Figure 2: The Age-Specific Prevalence Rates of Parkinson's Disease in the Elderly Among Five European Countries, 2003
- Figure 3: Parkinson's Disease, Global, Market Size Estimates ($bn), 2010-2020
- Figure 4: Proportion of Population 60 Years or Older, World, 1950-2050
- Figure 5: Points Distribution of UPDRS
- Figure 6: Distribution of Parkinson's patients by Hoehn & Yahr Classification
- Figure 7: Primary Endpoint, "Off Time" Reduction , Advanced Parkinson's Disease Phase III Study
- Figure 8: Secondary Endpoints, Improvement in UPDRS Parts II and III, Advanced Parkinson's Disease Phase III Study Results
- Figure 9: Drug Model Diagram of IPX066
- Figure 10: IPX066, Parkinson's Disease, Global, Sales Forecasts ($m), 2013-2020
- Figure 11: IPX066, Parkinson's Disease, The US, Sales Forecasts ($m), 2013-2020
- Figure 12: IPX066, Parkinson's Disease, The UK, Sales Forecasts ($m), 2013-2020
- Figure 13: IPX066, Parkinson's Disease, France, Sales Forecasts ($m), 2013-2020
- Figure 14: IPX066, Parkinson's Disease, Germany, Sales Forecasts ($m), 2013-2020
- Figure 15: IPX066, Parkinson's Disease, Italy, Sales Forecasts ($m), 2013-2020
- Figure 16: IPX066, Parkinson's Disease, Spain, Sales Forecasts ($m), 2013-2020
- Figure 17: IPX066, Parkinson's Disease, Global, Sales Distribution by Country ,2020
- Figure 18: Drug Model Diagram
- Figure 19: Patients Approved for the Drug
|
